TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Fish Oil Based Intravenous Fat Emulsions on the Epidermal Barrier Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with sever chronic intestinal disease requiring long term parenteral nutrition~* Receiving home lipid containing parenteral nutrition (LCPN), regardless of currently infused intravenous fat emulsion~* With a stable dose of LCPN for at least 1 month at recruitment time~* Administered at least 4 days a week through central venous access, with at least 150 mL of lipid per parenteral nutrition bag with lipid.~* Age \>18~* Being available for 2 medical consultations in a 6 month period~* Who gave its written informed consent to participate to the study and without legal protection~* Social security coverage~Exclusion Criteria:~* Lesser expected parenteral nutrition length than duration for the entire trial~* Dermatological criteria : History of skin disease (atopic dermatitis, psoriasis) or evolving skin disease, broken or inflamed skin on the TEWL measurement site, Use of topical creams on the TEWL measurement site, Skin or systemic allergy (asthma)~* Contraindication to one of the selected intravenous fat emulsion: Severe dyslipidemia; Uncontrolled diabetes; Sepsis; Severe hepatic impairment; Major blood clotting disorders; Egg protein, soybean, peanut or fish hyper sensibility; Serum creatinine clearance \< 30 ml/min

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- soybean oil (SO)-based IVFE (Medialipide) (Type: ACTIVE_COMPARATOR): None
- fish oil (FO)-containing IVFE (Lipidem) (Type: ACTIVE_COMPARATOR): fish oil (FO)-containing IVFE (Lipidem)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Oregano Ointment vs. Standard Treatment for Pediatric Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant female subjects aged 2-17 years of age.~* Individuals must be diagnosed with acute-subacute AD regardless of the study.~* Written informed consent must be obtained from all patients or caregivers.~* Women of childbearing potential (WOCBP) must be willing to practice effective contraception for the duration of study treatment.~* Subjects must be willing and able to comply with study conditions, properly apply or have caregivers apply topical medications to the selected body sites, as well as return to the clinic for required visits.~* Subject caregivers must be willing and able to perform ADQ assessment test.~Exclusion Criteria:~* Individuals who are immune-compromised or suffering from infectious disease, malignant disease, are known to be HIV+ or present with a general reduced level of health.~* Individuals diagnosed with underlying dermatological conditions in addition to AD.~* Individuals with a chronic pre-existing disease such as diabetes mellitus or others that in the opinion of the investigator would preclude their participation in the study.~* Individuals who are pregnant, nursing mothers, or subjects planning a pregnancy during the course of the study.~* Subjects/caregivers who are unable to communicate or comply with study conditions due to language disability, poor mental development, or impaired cerebral function.~* Individuals who are simultaneously enrolled in another clinical drug or device research study.~* Individuals with a history of chronic steroid use.~* Individuals needing to concurrently use topical agents, medicinal products containing corticosteroids, or immunosuppressants.~* Individuals who have received systemically administered corticosteroids and/or antihistamines 2 weeks prior to the start of study.~* Individuals undergoing light therapy.~* Individuals who have been treated with another investigation device or drug within 30 days prior to study enrollment.~* Individuals with a known allergy to oregano.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Standard: Hydrocortisone 1% ointment (Type: ACTIVE_COMPARATOR): Intervention: hydrocortisone 1% ointment will be applied to one patient's forearm
- Experimental: oregano extract cream (Type: EXPERIMENTAL): Intervention: Oregano extract cream for mild to moderate atopic dermatitis will be applied to the other patient's forearm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Genetic Drug Study of Mycophenolic Acid (CellCept) in Pediatric Kidney Transplant Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male subjects and non-pregnant female subjects aged 2 to 18 years who are about to receive a kidney transplant and will be on post transplant MMF containing immunosuppressive therapy.~* A signed and dated institutional review board (IRB) approved parental/guardian informed consent form and an IRB approved child assent form if applicable.~* Subjects with stable kidney allografts who are on a stable regimen of MMF (with tacrolimus and steroids)~* May have clinically important abnormalities on clinical and /or laboratory evaluations, only as these abnormalities relate to an underlying condition as determined by the principal investigator.~Exclusion Criteria:~* Children receiving cyclosporine therapy that may interact with MPA entero-hepatic recycling.~* Any medical condition(active or chronic) or prior surgery that may interfere with the pharmacokinetics of MMF as determined by the principal investigator.~* Concomitant medication that may interfere with the pharmacokinetics of MMF as determined by the principal investigator.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Wnt, Notch and Hedgehog Activity in Chemo-Naive Tumors Collected During Staging of Esophageal Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with an esophageal cancer and scheduled for a standard of care endoscopic ultrasound.~* Patient must sign a consent to be a participant in this protocol.~Exclusion Criteria:~* Patients not diagnosed with an esophageal cancer.~* Patients that have undergone a previous staging endoscopic ultrasound.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with Esophageal Cancer (Type: None): Tumor Biopsy via Ultrasound Endoscopy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two Initial Evaluation Scales of the Severity of Brain Injury Adults Patients on the Neurological Outcome at 6 Months

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All patients aged 18 years or more~* Potentially Victim of a cerebral injury whatever the level of severity~* Having a calculation of GCS and KBS on arrival at the hospital (emergency room)~* Affiliated to a social security scheme or benefiting through a third person.~Exclusion Criteria:~* Pregnant women~* Patients who refusing to participate in research~* Patients undergoing enhanced protection (persons deprived of liberty by a judicial or administrative decision, adults under legal protection).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Drum-Assisted Therapy for Native Americans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* meeting Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR; American Psychiatric Association, 2000) criteria of current alcohol or drug abuse or dependence~* self-identifying as at least ¼ American Indian/Alaska Native heritage~* seeking treatment for alcohol or drug abuse~* being at least 18 years old. Clients will be assessed for suitability for outpatient treatment.~Exclusion Criteria:~* have a psychiatric conditions that is not suitable for outpatient treatment (e.g., if they require inpatient rehabilitation treatment, have significant psychiatric disorders, require medical detoxification, or have significant medical problems)~* have a current suicidal ideation/plan as assessed by the ASI or BSI~* are mandated by the court to obtain treatment for substance abuse where such mandate requires the results of urine toxicology tests to be reported to the court~* expectation that the participant will fail to complete the study protocol due to probable incarceration or relocation from the clinic area.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Treatment-As-Usual (Type: ACTIVE_COMPARATOR): Substance Abuse treatment typically received
- DARTNA (Type: EXPERIMENTAL): 12-week DARTNA program

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Brief Mind-Body Bridging Intervention for Suicidal Ideation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects will be Veterans aged 18-80 admitted to Substance Abuse Residential Rehabilitation Treatment Program (SARRTP) with addictive disorders and/or co-occurring psychiatric disorder with suicide risk factors.~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Treatment as Usual (TAU) (Type: NO_INTERVENTION): Participants assigned to Treatment As Usual (TAU) will receive the normal standard of care treatment from the Suicide Prevention Team and the Mental Health Service which may include individual therapy, group therapy, and/or medication therapy, all as decided by the individual and his/her doctor. Treatment as usual also includes monitoring by the Suicide Prevention Team.
- Treatment As Usual with Mind-Body Bridging (TAU + MBB) (Type: EXPERIMENTAL): Participants assigned to TAU + MBB will will receive treatment from the Suicide Prevention Team and the Mental Health Service, AND will be asked to participate in consisting of three to eight 60-minute sessions that will occur consecutively. Each group will be led by a trained MBB facilitator. Participants will receive a workbook at the beginning of the training that contains an explanation of all the major concepts involved in Mind Body Bridging. The workbook has homework assignments to be completed daily between group sessions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: NNRTI/PI Toxicity Switch to Darunavir Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infected as documented by a licensed HIV-1 antibody ELISA test~* Subject is currently on an antiretroviral regimen comprising of at least three licensed antiretroviral agents including efavirenz, ritonavir-boosted lopinavir or ritonavir-boosted atazanavir~* Subject is virologically suppressed with a viral load \< 50 copies/ml~* Subject has a CD4+ count above 50 cells/ml~* If subject is a female of childbearing potential, she must agree to use a double barrier method of contraception~* No previous exposure to darunavir~Exclusion Criteria:~* Pregnant or lactating women~* Any female of childbearing potential not using effective birth control methods or not willing to continue practicing these birth control methods during the trial and for at least 30 days after the end of the trial (or after last intake of investigational ARVs)~* Heterosexually active male subject not using effective birth control methods or not willing to continue practicing these birth control methods during the trial and until 30 days after the end of the trial (or after last intake of investigational ARVs)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): Immediate switch from NNRTI/PI to DRV/r
- Group 2 (Type: ACTIVE_COMPARATOR): Switch after 10 weeks from NNRTI/PI to DRV/r

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dual-task Training in Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Between 60 and 95 Years Old~* Self-described as generally healthy~* Normal or corrected to normal vision~* Able to stand on one foot for at least 3 seconds with minimal sway and no loss of balance~Exclusion Criteria:~* Known neurologic disorder affecting mobility or cognition~* Self-reported known moderate or greater lower extremity arthritis~* Known disease process that affects muscle function~* Color Blindness~* Lower extremity pain in the previous 15 days~* Known learning or attention deficit~* Currently taking medication that affects attention, learning, and/or memory~* Known Cardiovascular Disease of previous heart attack or cardiomyopathy~* Chronic Kidney Disease~* Severe Obesity as defined by a BMI of greater than or equal to 40 Kg/m2

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 95 Years
- Healthy Volunteers: t

Study Arms:
- Dual Task Two (Type: EXPERIMENTAL): Participants perform a cognitive-motor dual-task where the motor task is the same for all groups and the simultaneously performed cognitive task is complex.
- Control (Type: ACTIVE_COMPARATOR): Participants perform only a motor-task that is the same for all groups (no simultaneous cognitive task).
- Dual Task One (Type: EXPERIMENTAL): Participants perform a cognitive-motor dual-task where the motor task is the same for all groups and the simultaneously performed cognitive task is simple.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Role of Individualized Versus Traditional Exercise in Combating Fatigue

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 to 70 years old~* Male or female~* With relapsing-remitting multiple sclerosis (RRMS) as defined by McDonald's 2010 criteria.~* Between 2 and 25 years from the onset of multiple sclerosis~* With a high level of fatigue, corresponding to a score of Fatigue Severity Scale\> 4 and Fatigue questionnaire \> 38.~* Expanded Disability Status Scale Score 5~* Testing ≥ 4 in all leg muscles.~* Ability to walk for 10 minutes without stopping (self-reported)~* Affiliates or beneficiaries of a social security scheme~* Having freely given their written consent after having been informed of the purpose, course of action and potential risks involved~Exclusion Criteria:~* Severe cerebellar spasticity or ataxia in either leg.~* Abnormal range of motion of the toes and/or ankle.~* Musculoskeletal injury that interferes with pedaling.~* High resting heart rate (\>90 beats per minute).~* Blood pressure \> 144/94 mmHg.~* Onset of a multiple sclerosis attack within 90 days prior to the study.~* Recent adjustment of any medication or drugs that may impact on fatigue, or taking stimulants for fatigue (e.g. Modafinil).~* Taking of neuro-active substances that may impair cortico-spinal excitability (hypnotics, antiepileptics, psychotropic drugs, muscle relaxants) throughout the study period.~* Contraindication to the application of a magnetic field~* History of co-morbid disease or conditions that would compromise the subject's safety during the study.~* Participation at the same time in another medical intervention study or having participated in such a study within 30 days prior to this study.~* Pregnant and Nursing Women~* Women of childbearing age without effective contraception~* Patient unable to understand the purpose and conditions of the study, incapable of giving consent~* Patient deprived of liberty or patient under guardianship

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Traditional exercise (Type: ACTIVE_COMPARATOR): fatigued multiple sclerosis patients with a traditional training program
- Individual exercise (Type: EXPERIMENTAL): tired multiple sclerosis patients with an adapted and individualized training program

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: EAGLE - Multicenter Study of the European Assessment Group for Lysis in the Eye

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subtotal central retinal artery occlusion or central retinal artery occlusion with choroidal hypoperfusion not lasting longer than 20h~* Patients aged from 18 years to 75 years (in case of pre-existing blindness of other eye also older than 75 years)~* Informed consent of the patient~Exclusion Criteria:~* Central retinal artery occlusion lasting longer than 20h~* Eye diseases, namely branch retinal artery occlusion, cilioretinal arteries supplying the macula, combined arterial-venous occlusion, proliferative diabetic retinopathy and elevated intraocular pressure (over 30 mmHg)~* Systemic diseases, namely severe general diseases, systemic arterial hypertension (systolic pressure \> 200 mmHg), despite medical therapy, acute systemic inflammation (erythrocyte sedimentation rate \> 30 mm within the first hour/ C-reactive protein \> 1,0 mg/dl), antithrombin-III deficiency in case of thrombocytopenia (\< 100000 per ml): pathologic clotting time, acute pancreatitis with elevated pancreas enzymes~* Medical History: heart attack within the last 6 weeks, intracerebral bleeding or neurosurgical operation within the last 4 weeks, therapy with marcumar/warfarin, allergic reaction to contrast agent, haemorrhagic diathesis, aneurysms, inflammatory vascular diseases (e.g., giant cell arteritis, Wegener´s granulomatosis), endocarditis, gastric ulcer~* Patient participation in other studies during the prior 4 weeks~* No willingness and ability of the patient to participate in all follow-up examinations~* Pregnancy~* Written consent not given~* Patient is not mobile (bedridden)~* Other conditions/ circumstances likely to lead to poor treatment adherence (e.g., history of poor compliance, alcohol or drug dependency, no fixed abode)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Local intra-arterial fibrinolysis (LIF)
- 2 (Type: ACTIVE_COMPARATOR): Conservative standard therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating Parent Engagement, Attachment, Stress, and Satisfaction With Remote Rounding in the NICU

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Parents with an infant admitted to the NICU/R4 with an anticipated length of stay of 2 weeks or more~2. Parent consents to study and answering questionnaires~3. English speaking~4. Infant is assigned to red or purple medical service team.~5. Infant age at enrollment: zero to 14 days old~Exclusion Criteria:~1. Parents with an infant admitted to the NICU/R4 with an anticipated length of stay less than 2 weeks~2. Parent is not willing to answer questionnaires~3. Non-English speaking~4. Patient is not assigned to red or purple medical service team.~5. Discharge to other than biological parents expected

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard Bedside Rounding (Type: NO_INTERVENTION): None
- Remote Bedside Rounding (Type: EXPERIMENTAL): Parents of infants on one care team will have the opportunity to participate in rounds via secure remote video software.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy